Group 1 - The core viewpoint of the report indicates that Keta Bio achieved a revenue of 163.35 million yuan in the first half of 2025, representing an 18.32% increase year-on-year, while the net profit attributable to shareholders decreased by 5.31% to 41.21 million yuan [1] - The net cash flow from operating activities was 27.88 million yuan, showing a significant decline of 44.47% compared to the previous year [1] - Research and development investment amounted to 16.74 million yuan, reflecting a year-on-year growth of 4.25% [1] Group 2 - Keta Bio strategically invested 20 million yuan in Qinghe Shixiang, acquiring a 7.14% stake to develop ready-to-eat probiotic products for teenagers, aiming to expand the ToC probiotic market [2] - The company established an overseas division to actively explore international markets and participated in the European International Nutrition and Health Food Exhibition to showcase the research progress and application value of "Chinese bacteria" [2] - The food sector's R&D production base Phase I project is progressing smoothly, with major construction completed and trial production expected to commence within 2025 [2] Group 3 - As of June 30, 2025, Keta Bio's total assets reached 1.94 billion yuan, a 1.46% increase from the end of the previous year, while the net assets attributable to shareholders grew by 0.09% to 1.79 billion yuan, indicating stable overall financial conditions [2]
科拓生物2025年上半年营业收入同比增长18.32%